Table 3 The change of volume, expenditures, and DDDc of policy-related antihypertensive drugs in the pre- and post-“4 + 7” periods
Volume (thousand DDD) | Expenditures (thousand CNY) | DDDc (CNY) | |||||||
|---|---|---|---|---|---|---|---|---|---|
Pre- | Post- | GR (%) | Pre- | Post- | GR (%) | Pre- | Post- | GR (%) | |
“4 + 7” List drugs | 24.53 | 47.13 | 92.15 | 73.81 | 37.44 | -49.28 | 3.01 | 0.79 | -73.60 |
Bid-winning drugs | 3.02 | 41.35 | 1268.54 | 5.76 | 17.66 | 206.42 | 1.91 | 0.43 | -77.61 |
Non-winning drugs | 21.51 | 5.78 | -73.11 | 68.05 | 19.78 | -70.93 | 3.16 | 3.42 | 8.11 |
Alternative drugs | 48.36 | 60.46 | 25.04 | 151.16 | 186.11 | 23.12 | 3.13 | 3.08 | -1.53 |
Overall policy-related | 72.89 | 107.60 | 47.63 | 224.97 | 223.55 | -0.63 | 3.09 | 2.08 | -32.69 |